Resolution of dupilumab-associated alopecia areata with dosage modification.

Kulkarni, Maansi; Rohan, Craig A; Morris, David; Travers, Jeffrey B

Kulkarni, Maansi; Rohan, Craig A; Morris, David; Travers, Jeffrey B.

Afiliación

Kulkarni M; Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright State University, Dayton, Ohio.
Rohan CA; Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright State University, Dayton, Ohio.
Morris D; Department of Dermatology, Boonshoft School of Medicine, Wright State University, Dayton, Ohio.
Travers JB; Dayton VA Medical Center, Dayton, Ohio.

JAAD Case Rep ; 22: 85-88, 2022 Apr.

Article en En | MEDLINE | ID: mdl-35340733

Palabras clave

AA, alopecia areata; AD, atopic dermatitis; BSA, body surface area; EASI, eczema area and severity index; IL, interleukin; alopecia areata; atopic dermatitis; autoimmunity; dupilumab

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: JAAD Case Rep Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google